Skip to main content
Terug
CI logo

Cigna Corporation

Datakwaliteit: 100%
CI
NYSE Healthcare Medical - Healthcare Plans
€ 265,87
▲ € 4,38 (1,68%)
Marktkapitalisatie: 71,02B
Dagbereik
€ 260,61 € 266,74
52-Weeksbereik
€ 239,51 € 350,00
Volume
1.319.764
50D / 200D Gem.
€ 277,87 / € 287,97
Vorige Slotkoers
€ 261,49

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 11,9 0,4
P/B 1,7 2,9
ROE % 14,4 3,7
Net Margin % 2,2 3,9
Rev Growth 5Y % 12,1 10,0
D/E 0,8 0,2

Koersdoel Analisten

Hold
€ 325,83 +22.6%
Low: € 300,00 High: € 375,00
Forward K/W
8,6
Forward WPA
€ 30,32
WPA Groei (sch.)
+0,0%
Omzet Sch.
280 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 45,90
€ 43,96 – € 48,40
 390 B 5
FY2029 € 41,01
€ 39,27 – € 43,24
 350 B 2
FY2028 € 37,09
€ 32,04 – € 41,58
 320 B 7

Belangrijkste Punten

Revenue grew 12,11% annually over 5 years — strong growth
Earnings grew 73,47% over the past year
ROE of 14,40% — decent returns on equity
Generating 8,39B in free cash flow
P/E of 11,92 — trading at a low valuation
PEG of 0,15 suggests growth is underpriced

Groei

Revenue Growth (5Y)
12,11%
Revenue (1Y)11,26%
Earnings (1Y)73,47%
FCF Growth (3Y)-9,49%

Kwaliteit

Return on Equity
14,40%
ROIC9,36%
Net Margin2,17%
Op. Margin3,32%

Veiligheid

Debt / Equity
0,75
Current Ratio0,85
Interest Coverage6,61

Waardering

P/E Ratio
11,92
P/B Ratio1,70
EV/EBITDA10,39
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 11,26% Revenue Growth (3Y) 18,66%
Earnings Growth (1Y) 73,47% Earnings Growth (3Y) 7,40%
Revenue Growth (5Y) 12,11% Earnings Growth (5Y) 2,63%
Profitability
Revenue (TTM) 274,95B Net Income (TTM) 5,96B
ROE 14,40% ROA 3,77%
Gross Margin 9,45% Operating Margin 3,32%
Net Margin 2,17% Free Cash Flow (TTM) 8,39B
ROIC 9,36% FCF Growth (3Y) -9,49%
Safety
Debt / Equity 0,75 Current Ratio 0,85
Interest Coverage 6,61 Dividend Yield 0,02%
Valuation
P/E Ratio 11,92 P/B Ratio 1,70
P/S Ratio 0,26 PEG Ratio 0,15
EV/EBITDA 10,39 Dividend Yield 0,02%
Market Cap 71,02B Enterprise Value 94,81B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 274,95B 247,12B 195,27B 180,52B 174,07B
Net Income 5,96B 3,43B 5,16B 6,70B 5,37B
EPS (Diluted) 22,17 12,12 17,39 21,41 15,75
Gross Profit 25,99B 25,96B 25,18B 23,50B 22,95B
Operating Income 9,13B 9,42B 8,54B 8,45B 7,94B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 157,92B 155,88B 152,76B 143,89B 154,89B
Total Liabilities 116,05B 114,64B 106,41B 98,98B 107,71B
Shareholders' Equity 41,71B 41,03B 46,22B 44,87B 47,11B
Total Debt 31,46B 31,97B 30,93B 31,55B 34,27B
Cash & Equivalents 7,68B 7,55B 7,82B 5,92B 5,08B
Current Assets 47,81B 48,87B 37,35B 30,12B 36,13B
Current Liabilities 56,34B 57,98B 48,72B 41,23B 43,57B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#91 of 1052
72
Growth Price/Sales Ratio Focus (Ken Fisher)
#273 of 618
39
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#153 of 332
53

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026